HIGHLIGHT
Epotiv

Epotiv

epoetin alfa

Manufacturer:

LG Chem Life Sciences

Distributor:

DKSH

Marketer:

LG Chem Life Sciences
Concise Prescribing Info
Contents
Recombinant human erythropoietin α
Indications/Uses
Symptomatic anemia & anemia requiring transfusion in chronic renal failure patients.
Dosage/Direction for Use
Chronic renal failure patients Initially 50 U/kg thrice wkly by slow SC or IV inj over 1-2 min. May increase dose by 25 U/kg every 4 wk. When increasing rate of Hb >2 g/dL after 50 U/kg administration, adjust dose by omitting 1 of the 3 doses/wk. If therapeutic effect is achieved, administer 25-50 U/kg 2-3x wkly as maintenance dose. Max: 200 U/kg in a single day thrice wkly. Patients on hemodialysis Inj treatment after hemodialysis. Patients w/ flu-like symptoms Inj treatment slowly over >5 min.
Contraindications
Hypersensitivity to erythropoietin or other erythropoietin prep. Patients w/ history of pure red cell anemia (PRCA) after treatment of erythropoietin prep; uncontrolled HTN.
Special Precautions
History of hypersensitivity & predisposition to allergy. Patients w/ HTN. History of MI, pulmonary & cerebral infarction in patients w/ a chance of thromboembolism. May exacerbate cerebral hemorrhage. Limit administration to patients w/ renal anemia; for patients w/ Hb <10 g/dL in case of renal anemia. Do not administer to the other anemia. Carefully monitor BP particularly in patients w/ CV disease or patients w/ chance of HTN; patients w/ vascular disease eg, MI, pulmonary embolism, CVA, or transient ischemic attack. Sufficient monitoring is required due to increased blood viscosity, & thromboembolism may exacerbate or induce. Premature w/ ventricular hemorrhage & intracerebral hemorrhage. Regularly monitor Hb & hematocrit during therapy, as once wkly in the early phase of treatment & once/every other wk in the maintenance phase. Discontinue & initiate appropriate treatments if hematopoiesis required is exceeded. Closely monitor BP & previously known neurologic symptoms. Hyperkalemia. Administer Fe supplement for Fe deficiency. Myeloid malignancies. Concomitant use w/ other erythropoietin prep. Consider marrow inspection in cases of pure red cell anemia w/ unknown causes. Pregnancy & lactation. Childn.
Adverse Reactions
Rise in BP, thrombosis of blood vessel contact region; hypertensive encephalopathy (headache, consciousness disorder, seizure); itch, rash, acne; hepatosis eg, AST, ALT, lactate dehydrogenase, alkaline phosphatase, total bilirubin; nausea, vomiting, anorexia & diarrhea; increased leukocyte, eosinophil, serum K, BUN, creatinine & uric acid,  decreased granulocyte, rickets; eye ground hemorrhage, splenomegaly, nasal hemorrhage, dizziness, pyrexia, slight fever, feeling of flush, malaise, arthralgia, myalgia, bitter taste of mouth, convulsion & blepharedma.
Drug Interactions
Not to be used concomitantly w/ other drugs.
ATC Classification
B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Presentation/Packing
Form
Epotiv soln for inj 4,000 IU/0.4 mL
Packing/Price
1's
Form
Epotiv soln for inj 10,000 IU/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in